Medarex, Inc.

Pharma companies enter into research agreement on antibody product

Published in Lab Law Weekly, June 10th, 2005

Ono Pharmaceutical Co., Ltd., and Medarex, Inc., (MEDX) announced that they have entered into a collaborative research agreement to research and develop a fully human antiPD-1 antibody for the potential treatment of cancer.

The parties have already started generating fully human antiPD-1 antibody product candidates under Ono's intellectual property regarding PD-1 and using Medarex's proprietary UltiMAb Human Antibody Development System, and they expect that clinical studies could begin in 12 to 24 months.

Under this arrangement, Ono and Medarex will jointly work toward potential commercialization of an antiPD-1 antibody. The two companies plan to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2005-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry